迪安诊断:2025一季报净利润-0.21亿 同比下降191.3%

Core Insights - The company reported a significant decline in key financial metrics for Q1 2025 compared to the same period in 2024, with a net profit of -0.21 billion yuan, representing a 191.3% decrease [1] - The basic earnings per share (EPS) dropped to -0.0344 yuan, a decline of 192.72% from the previous year [1] - The total revenue for Q1 2025 was 23.65 billion yuan, down 20.45% from 29.73 billion yuan in Q1 2024 [1] Financial Performance - Basic Earnings Per Share: -0.0344 yuan in Q1 2025 compared to 0.0371 yuan in Q1 2024, a decrease of 192.72% [1] - Net Profit: -0.21 billion yuan in Q1 2025, down from 0.23 billion yuan in Q1 2024, a decline of 191.3% [1] - Revenue: 23.65 billion yuan in Q1 2025, a decrease of 20.45% from 29.73 billion yuan in Q1 2024 [1] - Return on Equity: -0.32% in Q1 2025, a significant drop from 0.31% in Q1 2024, reflecting a 203.23% decline [1] Shareholder Information - The top ten unrestricted shareholders hold a total of 11,003.92 million shares, accounting for 21.95% of the circulating shares, with a decrease of 2,352.83 million shares from the previous period [1] - Notable shareholders include Chen Haibin with 4,110.97 million shares (8.20%) and Huabao Zhongzheng Medical ETF with 1,635.39 million shares (3.26%) [2] - Several shareholders exited the top ten list, including BNP Paribas and Goldman Sachs, indicating a shift in shareholder composition [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares in the current period [2]